|
|
|
Welcome to Cyplasin™
Cyplasin Biomedical Ltd. was founded to develop and commercialize a recombinant glycoprotein originally isolated from a marine organism known as the sea hare (Aplysia punctata). The protein
has shown high cytotoxicity against multiple
types of cancer cells, particularly those involving melanoma and skin
cancers. This protein seems to induce cell death via a cytotoxic effect
which occurs irreversibly at nanomolar concentrations of the protein.
However under these conditions normal cells appear to remain unharmed. Based on its CYtotoxicity, its possible effects
on neoPLAsia, and its origin, AplySIa, the
protein was termed CYPLASIN™. It is the intent of the company to move forward
with the development of Cyplasin for use as
an anti-cancer therapeutic agent initially
for melanoma and skin cancer and is called
Cyplasin-SC™. It is believed that Cyplasin-SC kills cancer cells
by triggering it’s
cytotoxicity effect via a cell surface receptor.
The data currently available (See How
Cyplasin Kills) demonstrates that Cyplasin-SC is able
to destroy the target skin cancer and melanoma tumor cells while leaving
normal healthy tissue unharmed. The company has initiated pilot preclinical trials for Cyplasin-SC which are
expected to demonstrate the efficacy/toxicity profile in animals. These studies
along with others will generate the data required for submission to the various
regulatory authorities to initiate the next step in product development, which
are clinical trials in humans. Cyplasin Biomedical Ltd., headquartered in Edmonton, Alberta, Canada. Most of
the current preclinical program is outsourced to competent third party Clinical
Research Organizations (CRO) located in Europe and North America. The company is public on the OTC Bulletin Board and Frankfurt Exchanges. |
Cyplasin Biomedical in the News
|
|
